GEP20022647B - Synergistic Combinations - Google Patents

Synergistic Combinations

Info

Publication number: GEP20022647B
Authority: GE; Georgia
Prior art keywords: cis; amino; derivative; oxathiolan; pyrimidin
Prior art date: 1995-03-30

Application number

GEAP19963898A

Other languages

English (en)

Inventor

Clair Martha Heider St

David Walter Barry

Original Assignee

The Wellcome Foundation Ltd Gb

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-30

Filing date

1996-03-28

Publication date

2002-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20022647(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-03-30 Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en

1995-03-30 Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en

1996-03-28 Application filed by The Wellcome Foundation Ltd Gb filed Critical The Wellcome Foundation Ltd Gb

2002-03-25 Publication of GEP20022647B publication Critical patent/GEP20022647B/en

Links

239000011885 synergistic combination Substances 0.000 title 1
239000002777 nucleoside Substances 0.000 abstract 2
150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
208000031886 HIV Infections Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
230000007721 medicinal effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Cephalosporin Compounds (AREA)
Medicinal Preparation (AREA)

GEAP19963898A 1995-03-30 1996-03-28 Synergistic Combinations GEP20022647B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9506489.5A GB9506489D0 (en)	1995-03-30	1995-03-30	Antiviral combinations
GBGB9506490.3A GB9506490D0 (en)	1995-03-30	1995-03-30	Antiviral combinations

Publications (1)

Publication Number	Publication Date
GEP20022647B true GEP20022647B (en)	2002-03-25

Family

ID=26306774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GEAP19963898A GEP20022647B (en)	1995-03-30	1996-03-28	Synergistic Combinations

Country Status (35)

Country	Link
US (1)	US6417191B1 (2)
EP (1)	EP0817637B1 (2)
JP (1)	JP2954357B2 (2)
KR (1)	KR100542536B1 (2)
CN (1)	CN1103593C (2)
AP (1)	AP652A (2)
AT (1)	ATE220551T1 (2)
AU (1)	AU715213B2 (2)
BR (3)	BRPI9607851B8 (2)
CA (1)	CA2216634C (2)
CZ (1)	CZ295940B6 (2)
DE (3)	DE69622386T2 (2)
DK (1)	DK0817637T3 (2)
EA (1)	EA000626B3 (2)
EE (1)	EE04047B1 (2)
ES (1)	ES2179193T3 (2)
FR (1)	FR05C0022I2 (2)
GE (1)	GEP20022647B (2)
HU (1)	HU224010B1 (2)
IL (1)	IL117727A (2)
LU (1)	LU91171I2 (2)
MX (1)	MX9707316A (2)
MY (1)	MY115461A (2)
NL (1)	NL300195I2 (2)
NO (2)	NO313787B1 (2)
NZ (1)	NZ306419A (2)
OA (1)	OA10616A (2)
PL (1)	PL187085B1 (2)
PT (1)	PT817637E (2)
RO (1)	RO117995B1 (2)
SI (1)	SI0817637T1 (2)
SK (1)	SK283825B6 (2)
TR (1)	TR199701074T1 (2)
UA (1)	UA60293C2 (2)
WO (1)	WO1996030025A1 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997049411A1 (en)	1996-06-25	1997-12-31	Glaxo Group Limited	Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6113920A (en) *	1996-10-31	2000-09-05	Glaxo Wellcome Inc.	Pharmaceutical compositions
TW536403B (en) *	1997-03-24	2003-06-11	Glaxo Group Ltd	An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) *	1997-05-17	1997-07-09	Glaxo Group Ltd	A novel salt
AU769660B2 (en) *	1997-05-17	2004-01-29	Glaxo Group Limited	Carbocyclic nucleoside hemisulfate and its use in treating viral infections
BR9809127A (pt) *	1997-05-17	2000-08-01	Glaxo Group Ltd	Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
GB9809213D0 (en) *	1998-04-29	1998-07-01	Glaxo Group Ltd	Pharmaceutical compositions
US6875773B1 (en)	1998-05-29	2005-04-05	Ben M. Dunn	Combination therapy for treatment of FIV infection
CA2374198A1 (en) *	1998-05-29	1999-12-02	Maki Arai	Combination therapy for treatment of fiv infection
GB9820417D0 (en) *	1998-09-18	1998-11-11	Glaxo Group Ltd	Antiviral combinations
US6432966B2 (en)	1999-10-29	2002-08-13	Smithkline Beecham Corporation	Antiviral combinations
US7074417B2 (en) *	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) *	2001-05-11	2011-03-24	Cipla Medpro Pty Ltd	Pharmaceutical composition.
AR040242A1 (es) *	2002-06-04	2005-03-23	Glaxo Group Ltd	Composiciones farmaceuticas
EA015145B1 (ru)	2003-01-14	2011-06-30	Джилид Сайэнс, Инк.	Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
KR20050119652A (ko)	2003-03-24	2005-12-21	에프. 호프만-라 로슈 아게	역전사 효소 저해제로서의 벤질-피리다진온
DE602004030369D1 (de)	2003-10-24	2011-01-13	Immunaid Pty Ltd	Therapieverfahren
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
EP1940781A1 (en)	2005-10-19	2008-07-09	F.Hoffmann-La Roche Ag	Phenyl-acetamide nnrt inhibitors
MX2009005881A (es)	2006-12-13	2009-06-12	Hoffmann La Roche	Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
JP5467870B2 (ja) *	2007-02-09	2014-04-09	アルファファームピーティーワイリミテッド	異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
PL2435825T3 (pl)	2009-05-27	2015-12-31	Biotempus Ltd	Sposoby leczenia chorób
UA105556C2 (uk)	2010-01-27	2014-05-26	Віів Гелскер Компані	Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
HK1220390A1 (zh)	2013-08-29	2017-05-05	Teva Pharmaceutical Industries Ltd.	包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
EP3129009A1 (en)	2014-04-08	2017-02-15	Teva Pharmaceutical Industries Ltd	Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN117164657A (zh)	2014-08-12	2023-12-05	莫纳什大学	定向淋巴的前药
EP3347340A4 (en)	2015-09-08	2019-01-23	Monash University	LYMPHENLEITUNGSPRODRUGS
US11883497B2 (en)	2017-08-29	2024-01-30	Puretech Lyt, Inc.	Lymphatic system-directing lipid prodrugs
WO2019046491A1 (en) *	2017-08-29	2019-03-07	Ariya Therapeutics, Inc.	LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11608345B1 (en)	2017-12-19	2023-03-21	Puretech Lyt, Inc.	Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en)	2017-12-19	2022-04-19	Puretech Lyt, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
AU2021217172A1 (en)	2020-02-05	2022-09-22	Monash University	Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4724232A (en) *	1985-03-16	1988-02-09	Burroughs Wellcome Co.	Treatment of human viral infections
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en)	1988-06-10	1992-06-16	Regents Of The University Of Minnesota	Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) *	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
DE69206876T3 (de)	1991-05-16	2004-08-12	Glaxo Group Ltd., Greenford	Nukleosidanalogen enthaltende Antiviren-Zubereitungen
WO1993023021A2 (en) *	1992-05-13	1993-11-25	The Wellcome Foundation Limited	Therapeutic combinations
US5723490A (en)	1992-09-08	1998-03-03	Vertex Pharmaceuticals Incorporated	THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en)	1994-08-26	1994-10-19	Wellcome Found	A novel salt
US5869461A (en)	1995-03-16	1999-02-09	Yale University	Reducing toxicity of L-nucleosides with D-nucleosides
ATE230267T1 (de)	1996-06-25	2003-01-15	Glaxo Group Ltd	Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
WO1997049411A1 (en)	1996-06-25	1997-12-31	Glaxo Group Limited	Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE10226522A1 (de) *	2002-06-14	2003-12-24	Degussa	Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

1996
- 1996-03-27 MY MYPI96001152A patent/MY115461A/en unknown
- 1996-03-28 CN CN96194050A patent/CN1103593C/zh not_active Expired - Lifetime
- 1996-03-28 BR BRPI9607851A patent/BRPI9607851B8/pt unknown
- 1996-03-28 BR BRPI9612992-1A patent/BRPI9612992B1/pt not_active IP Right Cessation
- 1996-03-28 PT PT96911953T patent/PT817637E/pt unknown
- 1996-03-28 UA UA97094740A patent/UA60293C2/uk unknown
- 1996-03-28 AT AT96911953T patent/ATE220551T1/de active
- 1996-03-28 EA EA199700203A patent/EA000626B3/ru not_active IP Right Cessation
- 1996-03-28 EP EP96911953A patent/EP0817637B1/en not_active Expired - Lifetime
- 1996-03-28 PL PL96322532A patent/PL187085B1/pl unknown
- 1996-03-28 CZ CZ19973090A patent/CZ295940B6/cs not_active IP Right Cessation
- 1996-03-28 GE GEAP19963898A patent/GEP20022647B/en unknown
- 1996-03-28 RO RO97-01795A patent/RO117995B1/ro unknown
- 1996-03-28 CA CA002216634A patent/CA2216634C/en not_active Expired - Lifetime
- 1996-03-28 BR BRPI9607851-0A patent/BR9607851B1/pt active IP Right Grant
- 1996-03-28 SK SK1295-97A patent/SK283825B6/sk not_active IP Right Cessation
- 1996-03-28 WO PCT/EP1996/001352 patent/WO1996030025A1/en not_active Ceased
- 1996-03-28 HU HU9801571A patent/HU224010B1/hu active Protection Beyond IP Right Term
- 1996-03-28 DE DE69622386T patent/DE69622386T2/de not_active Expired - Lifetime
- 1996-03-28 AU AU54972/96A patent/AU715213B2/en not_active Expired
- 1996-03-28 DK DK96911953T patent/DK0817637T3/da active
- 1996-03-28 US US08/930,225 patent/US6417191B1/en not_active Expired - Lifetime
- 1996-03-28 DE DE1996622386 patent/DE122005000029I2/de active Active
- 1996-03-28 NZ NZ306419A patent/NZ306419A/xx not_active IP Right Cessation
- 1996-03-28 TR TR97/01074T patent/TR199701074T1/xx unknown
- 1996-03-28 SI SI9630494T patent/SI0817637T1/xx unknown
- 1996-03-28 ES ES96911953T patent/ES2179193T3/es not_active Expired - Lifetime
- 1996-03-28 KR KR1019970706824A patent/KR100542536B1/ko not_active Expired - Lifetime
- 1996-03-28 MX MX9707316A patent/MX9707316A/es active IP Right Grant
- 1996-03-28 JP JP8528931A patent/JP2954357B2/ja not_active Expired - Lifetime
- 1996-03-28 DE DE200512000029 patent/DE122005000029I1/de active Pending
- 1996-03-28 AP APAP/P/1997/001089A patent/AP652A/en active
- 1996-03-28 EE EE9700240A patent/EE04047B1/xx not_active IP Right Cessation
- 1996-03-29 IL IL11772796A patent/IL117727A/xx not_active IP Right Cessation
1997
- 1997-09-17 OA OA70075A patent/OA10616A/en unknown
- 1997-09-29 NO NO19974510A patent/NO313787B1/no not_active IP Right Cessation
2005
- 2005-05-04 LU LU91171C patent/LU91171I2/fr unknown
- 2005-05-09 NL NL300195C patent/NL300195I2/nl unknown
- 2005-05-09 FR FR05C0022C patent/FR05C0022I2/fr active Active
- 2005-05-24 NO NO2005014C patent/NO2005014I2/no unknown

Also Published As

Publication number	Publication date
ATE220551T1 (de)	2002-08-15
CN1103593C (zh)	2003-03-26
JP2954357B2 (ja)	1999-09-27
NL300195I1 (nl)	2005-08-01
TR199701074T1 (xx)	1998-02-21
CA2216634C (en)	2004-07-20
CN1185110A (zh)	1998-06-17
AP9701089A0 (en)	1997-10-31
IL117727A0 (en)	1996-07-23
NZ306419A (en)	2000-01-28
PT817637E (pt)	2002-11-29
IL117727A (en)	1999-11-30
MX9707316A (es)	1997-11-29
SK283825B6 (sk)	2004-02-03
WO1996030025A1 (en)	1996-10-03
JPH10511682A (ja)	1998-11-10
HUP9801571A3 (en)	2001-04-28
EP0817637B1 (en)	2002-07-17
BRPI9612992B1 (pt)	2020-08-04
EP0817637A1 (en)	1998-01-14
DE69622386T2 (de)	2003-02-13
EA000626B3 (ru)	2016-04-29
NO313787B1 (no)	2002-12-02
FR05C0022I2 (2)	2005-10-21
SI0817637T1 (en)	2002-10-31
EA199700203A1 (ru)	1998-02-26
AU5497296A (en)	1996-10-16
OA10616A (en)	2001-03-15
AP652A (en)	1998-06-19
KR100542536B1 (ko)	2006-03-23
DE122005000029I1 (de)	2005-10-06
PL187085B1 (pl)	2004-05-31
BR9607851A (pt)	1998-07-21
BR9607851B1 (pt)	2009-01-13
DK0817637T3 (da)	2002-11-11
CZ295940B6 (cs)	2005-12-14
EA000626B1 (ru)	1999-12-29
UA60293C2 (uk)	2003-10-15
HU224010B1 (hu)	2005-04-28
ES2179193T3 (es)	2003-01-16
NO2005014I1 (no)	2005-06-06
FR05C0022I1 (2)	2005-06-10
NO2005014I2 (no)	2008-02-11
MY115461A (en)	2003-06-30
LU91171I9 (2)	2018-12-28
LU91171I2 (fr)	2005-07-04
NO974510D0 (no)	1997-09-29
BRPI9607851B8 (pt)	2019-11-05
KR19980703420A (ko)	1998-11-05
AU715213B2 (en)	2000-01-20
CA2216634A1 (en)	1996-10-03
CZ309097A3 (cs)	1998-05-13
RO117995B1 (ro)	2002-12-30
PL322532A1 (en)	1998-02-02
US6417191B1 (en)	2002-07-09
HK1009401A1 (en)	1999-09-10
SK129597A3 (en)	1998-07-08
DE122005000029I2 (de)	2006-04-27
HUP9801571A2 (hu)	1999-01-28
NO974510L (no)	1997-09-29
EE04047B1 (et)	2003-06-16
EE9700240A (et)	1998-04-15
NL300195I2 (nl)	2005-11-01
DE69622386D1 (de)	2002-08-22

Publication	Publication Date	Title
NZ306419A (en)	2000-01-28	Synergistic combinations of 1592U89, 3TC and optionally zidovudine or 1592U89, FTC and zidovudine
NO20053817L (no)	2005-10-13	Preparater og fremgangsmater for antiviral kombinasjonsterapi.
EP1062950A3 (en)	2003-05-02	1,3 Oxathiolane nucleoside analogues
RU94013464A (ru)	1995-12-10	Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
CA2404387A1 (en)	2001-10-11	Theanine compositions for promoting sleep
BR0214806A (pt)	2004-09-14	Composições farmacêuticos de 5,7,14-triazatetraciclo-{10.3.1.02,11.0,4,9]-hexadeca-2(1 1),3,5,7,9-penteno
BR9406893A (pt)	1996-09-10	Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
BR0311701A (pt)	2005-03-08	Formulação de dosagem multiparticulada com liberação controlada de lamotrigina, composição farmacêutica, processo para a preparação de uma composição farmacêutica de lamotrigina, método para a redução da flutuação no pico e no depósito da concentração da droga no plasma do sangue de um paciente, método para melhorar a complacência de um paciente pela redução da frequência de dosagem para uma vez por dia, método para a ministração mais segura de lamotrigina, método para proporcionar uma concentração terapêutica de plasma de sangue de lamotrigina e uso da formulação
IT1187687B (it)	1987-12-23	Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
AP9801419A0 (en)	1998-12-31	Combination comprising VX478, zidovudine, FTC and or 3
ES2054718T3 (es)	1994-08-16	El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
BR9808060A (pt)	2000-03-08	Composição farmacêutica, processos para tratamento de infecções virais pela administração de uma quantidade farmaceuticamente segura e eficaz de uma composição farmacêutica, uso da lamivudina ou um seu derivado farmaceuticamente aceitável, e, processo para a preparação de uma composição farmacêutica.
ES2130246T3 (es)	1999-07-01	Nucleosidos terapeuticos de la serie 2',3'-didesoxi-3'-fluoro-purina.
AR040242A1 (es)	2005-03-23	Composiciones farmaceuticas
BRPI0415322A (pt)	2006-12-05	composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
AR005551A1 (es)	1999-06-23	Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple
AR043332A1 (es)	2005-07-27	Composiciones y metodos para terapia antiviral
AR026255A1 (es)	2003-02-05	Combinaciones antivirales.
ES2189964T3 (es)	2003-07-16	Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
DE69316621D1 (de)	1998-02-26	Antivitale zusammensetzungen
WO2000018383A3 (en)	2000-07-06	Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
Gilden	1997	Three drugs now in expanded access
TH20892B (th)	2006-11-16	สิ่งผสมรวมซึ่งเสริมฤทธิ์กันของไซโดวูดีน 1592u89 และ 3tc
TH28828A (th)	1998-06-10	สิ่งผสมรวมซึ่งเสริมฤทธิ์กันของไซโดวูดีน 1592u89 และ 3tc
Gilden et al.	1996	Three days that shook the world